Pfizer Inc (PFE) FY2025 10-K Annual Report
Pfizer Inc (PFE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Pfizer Inc FY2025 10-K Analysis
Business Overview
- • Global pharma innovator generating 65% of revenues from 12 products >$1B each; Eliquis alone = 13% of total revenues in 2025
- • Chantix returned to U.S. market in 2025 after 2021 recall; Oxbryta voluntarily withdrawn globally following negative benefit-risk assessment
- • Voluntary MFN Agreement signed with Trump Administration in September 2025 — three-year Section 232 tariff exemption contingent on increased U.S. manufacturing investment
- • 41% of 2025 revenues from international operations (21% Europe, 12% China/Japan/Asia Pacific); intense generic competition in China cited as ongoing pressure
- • OBBBA passed July 4, 2025 estimated to raise U.S. uninsured population by 10 million, directly threatening product demand
Management Discussion & Analysis
- • Revenue $62.2B in 2025, up ~$0.7B (~1%) YoY from $63.6B in 2024; international ops $25.5B (41% of total)
- • IRA Medicare Part D Redesign negatively impacted 2025 revenues by ~$1B; Eliquis alone = 13% of total revenues
- • Oncology (Seagen-driven ADCs: Padcev, Adcetris, Tivdak) best-performing growth area; COVID products (Comirnaty, Paxlovid) continued multi-year revenue decline
- • Capex included ~$125M environment-related; ~$500M R&D savings from cost-base realignment program to be reinvested in R&D in 2026; Metsera acquired November 2025
- • Key risks: patent cliff 2026–2030 accelerating, MFN/TrumpRx pricing agreement with U.S. government, tariff exposure (3-year Section 232 grace period secured), IRA MDPNP expanding to Ibrance and Xtandi effective 2027
Risk Factors
- • IRA Medicare Drug Price Negotiation Program: Eliquis, Ibrance, Xtandi, and Xeljanz selected for Maximum Fair Price; IRA Part D Redesign already hit 2025 revenues ~$1B
- • OBBBA (enacted July 4, 2025) cuts Medicaid/ACA funding; CBO estimates 10M more uninsured, threatening product demand and pricing
- • Revenue concentration risk: 12 products = 65% of total revenues in 2025; Eliquis alone = 13%, with patent expiry and IRA Maximum Fair Price effective January 1, 2026
- • China VBP/QCE generic competition intensifying; China = 5% of total revenues with accelerating price cuts on off-patent products
- • MFN Agreement with Trump Administration: discounts up to 85% on TrumpRx.gov platform, average ~50%, with binding final terms still being negotiated
Pfizer Inc FY2025 Key Financial MetricsXBRL
Revenue
$62.6B
▼ -1.6% YoY
Net Income
$7.8B
▼ -3.2% YoY
Net Margin
12.4%
▼ -20bp YoY
ROE
9.0%
▼ -12bp YoY
Total Assets
$208.2B
▼ -2.5% YoY
EPS (Diluted)
$1.36
▼ -3.5% YoY
Operating Cash Flow
$11.7B
▼ -8.2% YoY
Source: XBRL data from Pfizer Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Pfizer Inc Annual Reports
Get deeper insights on Pfizer Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.